Cost-effectiveness of mass screening for dipstick hematuria in Japan

2022 ◽  
Author(s):  
Reiko Okubo ◽  
Shu-Ling Hoshi ◽  
Tomokazu Kimura ◽  
Masahide Kondo ◽  
Koichi Asahi ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Mass Screening

scholarly journals Cost-Effectiveness Analysis of Mass Screening for Cervical Cancer in Japan

1997 ◽  
Vol 7 (3) ◽  
pp. 135-141 ◽  
Author(s):  
Gen Matsunaga ◽  
Ichiro Tsuji ◽  
Shinji Sato ◽  
Akira Fukao ◽  
Shigeru Hisamichi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cost Effectiveness ◽  
Mass Screening ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden

2013 ◽  
Vol 12 (1) ◽  
Author(s):  
Valerie Crowell ◽  
Olivier JT Briët ◽  
Diggory Hardy ◽  
Nakul Chitnis ◽  
Nicolas Maire ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Cost Effectiveness ◽  
Falciparum Malaria ◽  
Mass Screening ◽  
Plasmodium Falciparum Malaria ◽  
Malaria Burden ◽  
The Cost

Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France

2004 ◽  
Vol 13 (3) ◽  
pp. 227-238 ◽  
Author(s):  
Célia Berchi ◽  
Véronique Bouvier ◽  
Jean-Marie Réaud ◽  
Guy Launoy
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Mass Screening ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data

PLoS ONE ◽  
2019 ◽  
Vol 14 (11) ◽  
pp. e0224479 ◽  
Author(s):  
Neill Booth ◽  
Pekka Rissanen ◽  
Teuvo L. J. Tammela ◽  
Paula Kujala ◽  
Ulf-Håkan Stenman ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Randomised Controlled Trial ◽  
Mass Screening ◽  
Controlled Trial ◽  
Cost Effectiveness Analysis ◽  
Register Data ◽  
Effectiveness Analysis ◽  
Randomised Controlled

scholarly journals Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison

2021 ◽  
pp. 103394
Author(s):  
Zoe Ward ◽  
Nyashadzaishe Mafirakureva ◽  
Jack Stone ◽  
Mary Keevans ◽  
Graham Betts-Symonds ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Mass Screening

scholarly journals Low Yield of Methicillin-Resistant Staphylococcus aureus Screening in Hemodialysis Patients: 10 Years’ Experience

2015 ◽  
Vol 36 (9) ◽  
pp. 1046-1049
Author(s):  
H. M. Gebreselassie ◽  
T. Kaspar ◽  
S. Droz ◽  
J. Marschall
Keyword(s):  
Staphylococcus Aureus ◽  
Cost Effectiveness ◽  
Mass Screening ◽  
Hemodialysis Patients ◽  
Alternative Strategy ◽  
High Risk Population ◽  
Care Hospital ◽  
Methicillin Resistant ◽  
Total Cost ◽  
Screening Approach

OBJECTIVETo determine the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in hemodialysis patients and to analyze the cost-effectiveness of our screening approach compared with an alternative strategy.DESIGNScreening study and cost-effectiveness analysis.METHODSAnalysis of twice-yearly MRSA prevalence studies conducted in the hemodialysis unit of a 950-bed tertiary care hospital from January 1, 2004, through December 31, 2013. For this purpose, nasal swab samples were cultured on MRSA screening agar (mannitol-oxacillin biplate).RESULTSThere were 20 mass screenings during the 10-year study period. We identified 415 patients participating in at least 1 screening, with an average of 4.5 screenings per patient. Of 415 screened patients, 15 (3.6%) were found to be MRSA carriers. The first mass screening in 2004 yielded the highest percentage of MRSA (6/101 [6%]). Only 7 subsequent screenings revealed new MRSA carriers, whereas 4 screenings confirmed previously known carriers, and 8 remained negative. None of the carriers developed MRSA bacteremia during the study period. The total cost of our screening approach, that is, screening and isolation costs, was US $93,930. The total cost of an alternative strategy (ie, no mass screening administered) would be equivalent to costs of isolation of index cases and contact tracing was estimated to be US $5,382 (difference, US $88,548).CONCLUSIONSIn an area of low MRSA endemicity (<5%), regular nasal screenings of a high-risk population yielded a low rate of MRSA carriers. Twice-yearly MRSA screening of dialysis patients is unlikely to be cost-effective if MRSA prevalence is low.Infect. Control Hosp. Epidemiol. 2015;36(9):1046–1049

scholarly journals Is mass screening for coeliac disease a wise use of resources? A health economic evaluation

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Fredrik Norström ◽  
Anna Myléus ◽  
Katrina Nordyke ◽  
Annelie Carlsson ◽  
Lotta Högberg ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Coeliac Disease ◽  
Mass Screening ◽  
Health Economic Evaluation ◽  
Cost Effective ◽  
Life Course Perspective ◽  
Sensitivity Analyses ◽  
Rapid Progression ◽  
Use Of Resources ◽  
The Cost

Abstract Background Living with undiagnosed symptomatic coeliac disease is connected with deteriorated health, and persons with coeliac disease often wait a long time for their diagnosis. A mass screening would lower the delay, but its cost-effectiveness is still unclear. Our aim was to determine the cost-effectiveness of a coeliac disease mass screening at 12 years of age, taking a life course perspective on future benefits and drawbacks. Methods The cost-effectiveness was derived as cost per quality-adjusted life-year (QALY) using a Markov model. As a basis for our assumptions, we mainly used information from the Exploring the Iceberg of Celiacs in Sweden (ETICS) study, a school-based screening conducted in 2005/2006 and 2009/2010, where 13,279 12-year-old children participated and 240 were diagnosed with coeliac disease, and a study involving members of the Swedish Coeliac Association with 1031 adult participants. Results The cost for coeliac disease screening was 40,105 Euro per gained QALY. Sensitivity analyses support screening based on high compliance to a gluten-free diet, rapid progression from symptom-free coeliac disease to coeliac disease with symptoms, long delay from celiac disease with symptoms to diagnosis, and a low QALY score for undiagnosed coeliac disease cases. Conclusions A coeliac disease mass screening is cost-effective based on the commonly used threshold of 50,000 Euro per gained QALY. However, this is based on many assumptions, especially regarding the natural history of coeliac disease and the effects on long-term health for individuals with coeliac disease still eating gluten.

Sign in / Sign up

Export Citation Format

Share Document